Radiopharm Theranostics, Ltd

This early-phase study tests a new drug called 177Lu-RAD202, which is a radioactive antibody that seeks out and attaches to HER2 proteins on cancer cells. The goal is to see if it is safe and to find the right dose for people with advanced solid tumors that have not responded to …

This early-phase study tests a new drug called 177Lu-RAD204, which is a radioactive antibody that seeks out and attaches to a protein (PD-L1) on cancer cells. The goal is to see if it is safe and tolerable for people with advanced solid tumors like lung, breast, or skin cancer th…

This early-phase study tests a new treatment called 177LuBetaBart for people with advanced solid tumors that have stopped responding to standard therapies. The treatment combines a targeting antibody with a radioactive particle to deliver radiation directly to cancer cells. The s…

This study tests a new radioactive drug (161Tb-RAD402) designed to find and attack prostate cancer cells that no longer respond to standard hormone therapy. About 73 men with castration-resistant prostate cancer will receive the drug to see if it is safe and can shrink tumors or …

This early-phase study is testing a new substance called RAD301 in 9 healthy volunteers and people with certain cancers (pancreatic, lung, esophageal, cervical, endometrial, or ovarian). The goal is to see how the body absorbs and handles the radiation from RAD301, and whether it…